Epileptic Disorders
MENUAdjunctive lacosamide for focal epilepsy: an open-label trial evaluating the impact of flexible titration and dosing on safety and seizure outcomes Volume 19, issue 2, June 2017
Authors
Aims
1 IHU-ICM and Department of Neurology, Pitié-Salpêtrière Hospital, Paris
2 UCB Pharma, Colombes, France
3 UCB Pharma, Raleigh, USA
4 UCB Pharma, Brussels, Belgium
5 Neurophysiology Clinic, University Hospital La Timone (AP-HM), Marseille
6 IHU-ICM and Department of Neurosurgery, Pitié-Salpêtrière Hospital, Paris, France
* Correspondence: Michel Baulac
Clinique Neurologique,
Hôpital de la Pitié-Salpêtrière,
47-83 Boulevard de l’Hôpital,
Paris 75013, France
- Key words: focal, seizure, dizziness, flexible dose, a, tiepileptic, individualised, titration
- DOI : 10.1684/epd.2017.0907
- Page(s) : 186-94
- Published in: 2017
To evaluate the safety and effectiveness of lacosamide in a real-life setting with the use of a flexible dose titration schedule and individualised maintenance doses up to the maximum approved dose of 400 mg/day.